Invitation to presentation of Immunovia´s interim report January – March 2020 on April 28, 2020
LUND (Sweden) – Immunovia invites to a teleconference (in English) for investors, analysts and media on Tuesday, April 28th, 2020 at 16:30 CET. Immunovia will publish the company’s interim report on April 28th, 2020 at 16:00 CET.
Mats Grahn, CEO will present Immunovia and comment on the interim report for the period January – March 2020 followed by a Q&A session.
Please call in a few minutes in advance. To attend, please dial-in at one of the numbers below and provide the conference code Immunovia to the operator:
Sweden: +46 (0) 8 50520424
United Sates: +1 212 999 6659
France: +33 (0) 1 7099 4740
Denmark: +45 3271 4573
Germany: +49 (0) 69 7104 45598
Spain: +34 91 788 9854
Netherlands: +31 (0) 20 794 8426
Norway: +47 2 156 3318
Austria: +43 (0) 12530807
Switzerland: +41 (0) 43 456 9986
UK (standard international access): +44 (0) 20 3003 2666
Conference Code: (to provide to the operator) Immunovia
Immunovia Webcast: https://channel.royalcast.com/ webcast / immunovia / 20200428_1 /
For more information, please contact:
Julie Silber, Director of Investor Relations, Immunovia
Tel: +46 7 93 486 277
There will be an MP3-file available at Immunovia’s webpage under Investors/Financial Reports (http://immunovia.com/investors/financial-reports/) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”.
The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world’s largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently entering the final validation for sales start Q3 2020. When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.